Alpha 2.0
Login Register
» Articles » PMID: 38278621

MASLD Emerging from the Fog of Fatty Liver

Overview
Journal J Hepatol
Publisher Elsevier
Specialty Gastroenterology
Date 2024 Jan 26
PMID 38278621
Authors
Giulio Marchesini
Roberto Vettor
Massimo Pinzani
Affiliations
Soon will be listed here.
Citing Articles

Lean MASLD and IBD: Exploring the Intersection of Metabolic Dysfunction and the Gut-Liver Axis.

Rotaru A, Stafie R, Stratina E, Zenovia S, Nastasa R, Minea H Life (Basel). 2025; 15(2).

PMID: 40003697 PMC: 11856855. DOI: 10.3390/life15020288.

Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024).

Fan J, Xu X, Yang R, Nan Y, Wei L, Jia J J Clin Transl Hepatol. 2024; 12(11):955-974.

PMID: 39544247 PMC: 11557364. DOI: 10.14218/JCTH.2024.00311.

Metabolic Dysfunction-Associated Steatotic Liver Disease MASLD: Jordan's Perspective Based on Knowledge and Attitude Determinants.

Alqudah O, Alshahwan H, Alsamhouri J, Yamin S, Kaffaf A, Alassaf M Risk Manag Healthc Policy. 2024; 17:2483-2491.

PMID: 39463728 PMC: 11512787. DOI: 10.2147/RMHP.S481401.

Liver segmental volumes and their relationship with 5-year prognostication.

Catucci D, Hrycyk J, Lange N, Obmann V, Berzigotti A, Bronnimann M Abdom Radiol (NY). 2024; 50(3):1133-1142.

PMID: 39254712 PMC: 11821769. DOI: 10.1007/s00261-024-04552-w.

Potential of Chlorogenic Acid in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Animal Studies and Clinical Trials-A Narrative Review.

Ziolkiewicz A, Nizinski P, Soja J, Oniszczuk T, Combrzynski M, Kondracka A Metabolites. 2024; 14(6).

PMID: 38921480 PMC: 11205996. DOI: 10.3390/metabo14060346.